Mateus C - Search Results

1

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.

Sun C, Wang L, Huang S, Heynen GJ, Prahallad A, Robert C, Haanen J, Blank C, Wesseling J, Willems SM, Zecchin D, Hobor S, Bajpe PK, Lieftink C, Mateus C, Vagner S, Grernrum W, Hofland I, Schlicker A, Wessels LF, Beijersbergen RL, Bardelli A, Di Nicolantonio F, Eggermont AM, Bernards R. Sun C, et al. Among authors: mateus c. Nature. 2014 Apr 3;508(7494):118-22. doi: 10.1038/nature13121. Epub 2014 Mar 26. Nature. 2014. PMID: 24670642 Free article.

2

eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies.

Boussemart L, Malka-Mahieu H, Girault I, Allard D, Hemmingsson O, Tomasic G, Thomas M, Basmadjian C, Ribeiro N, Thuaud F, Mateus C, Routier E, Kamsu-Kom N, Agoussi S, Eggermont AM, Désaubry L, Robert C, Vagner S. Boussemart L, et al. Among authors: mateus c. Nature. 2014 Sep 4;513(7516):105-9. doi: 10.1038/nature13572. Epub 2014 Jul 27. Nature. 2014. PMID: 25079330

3

[New treatments for metastatic melanoma: a first hope].

Robert C, Mateus C. Robert C, et al. Among authors: mateus c. Rev Prat. 2011 Nov;61(9 Suppl):S1-2. Rev Prat. 2011. PMID: 22338196 Review. French. No abstract available.

4

[Immunotherapies and melanoma].

Routier É, Robert C, Mateus C. Routier É, et al. Among authors: mateus c. Bull Cancer. 2014 Dec;101 Suppl 2:S13-24. doi: 10.1684/bdc.2014.2054. Bull Cancer. 2014. PMID: 25776763 Review. French.

5

[Anti-CTLA-4 monoclonal antibody: a major step in the treatment of metastatic melanoma].

Robert C, Mateus C. Robert C, et al. Among authors: mateus c. Med Sci (Paris). 2011 Oct;27(10):850-8. doi: 10.1051/medsci/20112710013. Epub 2011 Oct 21. Med Sci (Paris). 2011. PMID: 22027422 Free article. Review. French.

6

[Major therapeutic advances in the treatment of metastatic melanoma].

Mateus C, Robert C. Mateus C, et al. Bull Cancer. 2012 Jun;99(6):619-25. doi: 10.1684/bdc.2012.1594. Bull Cancer. 2012. PMID: 22652330 Review. French.

7

[Detection of residual microscopic disease in melanoma: interest of the sentinel lymph node procedure?].

Mateus C, Thomas M, Robert C. Mateus C, et al. Bull Cancer. 2014 Apr;101(4):354-7. doi: 10.1684/bdc.2014.1943. Bull Cancer. 2014. PMID: 24793626 Review. French.

8

An epitranscriptomic mechanism underlies selective mRNA translation remodelling in melanoma persister cells.

Shen S, Faouzi S, Bastide A, Martineau S, Malka-Mahieu H, Fu Y, Sun X, Mateus C, Routier E, Roy S, Desaubry L, André F, Eggermont A, David A, Scoazec JY, Vagner S, Robert C. Shen S, et al. Among authors: mateus c. Nat Commun. 2019 Dec 16;10(1):5713. doi: 10.1038/s41467-019-13360-6. Nat Commun. 2019. PMID: 31844050 Free PMC article.

9

MAP-kinase pathway up or down? Just look at the skin of your patients!

Robert C, Thomas M, Mateus C. Robert C, et al. Among authors: mateus c. Melanoma Res. 2014 Oct;24(5):421-3. doi: 10.1097/CMR.0000000000000114. Melanoma Res. 2014. PMID: 25185691 No abstract available.

10

Advances in the management of cutaneous toxicities of targeted therapies.

Robert C, Sibaud V, Mateus C, Cherpelis BS. Robert C, et al. Among authors: mateus c. Semin Oncol. 2012 Apr;39(2):227-40. doi: 10.1053/j.seminoncol.2012.01.009. Semin Oncol. 2012. PMID: 22484194 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

298 results

Search Page

Filters